𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Small, dense low-density-lipoproteins and the metabolic syndrome

✍ Scribed by Manfredi Rizzo; Kaspar Berneis

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
263 KB
Volume
23
Category
Article
ISSN
1520-7552

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Small, dense low‐density‐lipoproteins (LDL) are associated with increased risk for cardiovascular diseases and diabetes mellitus and a reduction in LDL size has been reported in patients with coronary and non‐coronary forms of atherosclerosis. LDL size has been accepted as an important predictor of cardiovascular events and progression of coronary artery disease as well as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Small, dense LDL, with elevated triglyceride levels and low HDL‐cholesterol concentrations, constitute the ‘atherogenic lipoprotein phenotype (ALP)’, a form of atherogenic dyslipidemia that is a feature of type 2 diabetes and the metabolic syndrome. LDL size and subclasses show specific alterations in patients with the metabolic syndrome that probably significantly increase their cardiovascular risk; however, so far it has not been recommended to incorporate LDL size measurements in treatment plans, when hypolipidemic therapies are installed. Patients with type 2 diabetes are at high cardiovascular risk and it is still on debate if the treatment goals may be identical or whether there are distinct groups with different cardiovascular risks and hence with different treatment goals. Measurements beyond traditional lipids, such as measurements on the presence of small, dense LDL in patients with the metabolic syndrome, may help to identify cardiovascular risk subgroups. In addition, it might be possible in the future to individualize hypolipidemic treatments if more than the traditional lipids are taken into account. LDL size measurement may potentially help to assess cardiovascular risk within the metabolic syndrome and adapt the treatment goals thereafter. Copyright © 2006 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Serum pseudocholinesterase and very-low-
Serum pseudocholinesterase and very-low-density lipoprotein metabolism
✍ Dr. K. M. Kutty; R. H. Payne 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 454 KB

Serum pseudocholinesterase (PChE) was discovered in 1932. Since this protein mimics many of the catalytic properties of acetylcholinesterase, it has traditionally been referred to as PChE, even though its true biological function is unknown. Serum PChE is synthesized in the liver and secreted into t

Microchip-based small, dense low-density
Microchip-based small, dense low-density lipoproteins assay for coronary heart disease risk assessment
✍ Hua Wang; Hui-Min Wang; Qing-Hui Jin; Hui Cong; Gui-Sheng Zhuang; Jian-Long Zhao 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 494 KB

## Abstract Small, dense low‐density lipoprotein (sdLDL) has been accepted as an emerging cardiovascular risk factor, and there has been an increasing interest in analytical methods for sdLDL profiling for diagnosis. Serum sdLDL may be measured by different laboratory techniques, but all these meth

Regulation of low-density lipoprotein me
Regulation of low-density lipoprotein metabolism by cell density and proliferative state
✍ R. Kenagy; E. L. Bierman; S. Schwartz 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 487 KB

Stimulation of the proliferation of human skin fibroblasts by platelet-derived growth factor increased the binding and degradation of low-density lipoproteins at cell densities of 2000-30,000 cells/cm2. Binding and degradation of low-density lipoprotein was an inverse function of cell density in bot

Very low density lipoprotein and low den
Very low density lipoprotein and low density lipoprotein isolated from patients with hepatitis C infection induce altered cellular lipid metabolism
✍ Mariarosaria Napolitano; Alessandro Giuliani; Tonino Alonzi; Carmine Mancone; Gi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB

## Abstract Several abnormalities of lipid metabolism, including hypo‐β‐lipoproteinemia and liver steatosis are associated with infection by hepatitis C virus (HCV). The aim of this study was to determine whether circulating lipoproteins of patients with HCV infection could directly cause alteratio

The effect of pasteurisation and freezin
The effect of pasteurisation and freezing on the low density lipoproteins of egg
✍ T. Lawrence Parkinson 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB

## Abstract The low density fraction of egg yolk was separated by gel filtration into two groups of lipoproteins. One group (1) had an extremely high molecular weight and was probably formed by aggregation of the second group (2), which itself had a high molecular weight. In liquid egg the ratio of

The inhibition by quercetin and ganhuang
The inhibition by quercetin and ganhuangenin on oxidatively modified low density lipoprotein
✍ Beong Ou Lim; Byung Pal Yu; Seong Il Cho; Erk Her; Dong Ki Park 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Oxidatively modified low-density lipoproteins (ox-LDL) have been strongly implicated in the pathogenesis of atherosclerosis. Both in vivo and in vitro experiments have shown that antioxidant treatment can attenuate oxidative damage from LDL. The aim of this study was to establish whether the ox-LDL